CANbridge’s CAN103 showed strong efficacy in pivotal trials and in July 2025 its Gaurunning® velaglucerase-beta was prescribed for the first time in China for types I/III Gaucher . https://www.datamintelligence.com/research-report/gaucher-disease-pipeline-insights